Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases

Source :: Legal Monitor Worldwide. June 8, 2021
Publication Year :: 2021
Abstract: (GlobeNewswire) - Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational research collaboration with the Kennedy Institute for [...]

Subjects :: Medical research -- Investigations
Medicine, Experimental -- Investigations
T cells -- Investigations
Monoclonal antibodies -- Investigations
Company legal issue
Business, international
Law

Tools